Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory A Masters

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
Lung Cancer (Amsterdam, Netherlands)|June 18, 2011
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancerRadj Gervais, John D Hainsworth, Normand Blais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateGregory A Masters, Sarah Temin, Christopher G Azzoli, et al.
Cancer|April 20, 2022
Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient surveyJennifer A Ligibel, Lori J Pierce, Catherine M Bender, et al.
JAMA Network Open|October 24, 2024
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538Michael K Farris, Michael D Mix, Xiaofei Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network studySteven Attia, Anne M Traynor, Kyungmann Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 studyGlenwood D Goss, Chris O'Callaghan, Ian Lorimer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation StudyJean-Louis Pujol, Tommaso De Pas, Achim Rittmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2013
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyJyoti D Patel, Lada Krilov, Sylvia Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung CancerJeffrey D Bradley, Chen Hu, Ritsuko R Komaki, et al.
Cancer Research Communications|September 20, 2023
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLCJoanne B Weidhaas, Chen Hu, Ritsuko Komaki, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|June 18, 2011
Phase II study of sunitinib as maintenance therapy in patients with locally advanced or metastatic non-small cell lung cancerRadj Gervais, John D Hainsworth, Normand Blais, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 2, 2015
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline UpdateGregory A Masters, Sarah Temin, Christopher G Azzoli, et al.
Cancer|April 20, 2022
Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient surveyJennifer A Ligibel, Lori J Pierce, Catherine M Bender, et al.
JAMA Network Open|October 24, 2024
Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538Michael K Farris, Michael D Mix, Xiaofei Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 2, 2008
Phase I/II study of vinorelbine and exisulind as first-line treatment of advanced non-small cell lung cancer in patients at least 70 years old: a wisconsin oncology network studySteven Attia, Anne M Traynor, Kyungmann Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 28, 2013
Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 studyGlenwood D Goss, Chris O'Callaghan, Ian Lorimer, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 22, 2016
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non-Small Cell Lung Cancer: A Phase I Dose Escalation StudyJean-Louis Pujol, Tommaso De Pas, Achim Rittmeyer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 12, 2013
Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical OncologyJyoti D Patel, Lada Krilov, Sylvia Adams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2019
Long-Term Results of NRG Oncology RTOG 0617: Standard- Versus High-Dose Chemoradiotherapy With or Without Cetuximab for Unresectable Stage III Non-Small-Cell Lung CancerJeffrey D Bradley, Chen Hu, Ritsuko R Komaki, et al.
Cancer Research Communications|September 20, 2023
The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLCJoanne B Weidhaas, Chen Hu, Ritsuko Komaki, et al.
Pageof 5